MUMBAI: Awash with financing options from venture capital firms, the best of the biotech startups are at a pole position, getting picky and pricey about deals with their larger pharma peers, Kemal Malik, who helms the global innovations unit at Bayer, the $55-billion German healthcare-to-agriculture Read more here: Biotech startups choosy on deals with big pharma: Bayer executive
Read More Here: Biotech startups choosy on deals with big pharma: Bayer executive
No comments:
Post a Comment